Clinical trials sponsored by Zhejiang Cancer Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Zhejiang Cancer Hospital

• A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
  NCT07330544 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
  NCT06349044 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
  NCT07235930 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
  NCT07602907 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
  NCT07284836 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
  NCT07014410 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
  NCT07162714 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
  NCT06214195 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
  NCT06538896 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
  NCT06784921 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
  NCT06609551 · Phase: Phase 3 · Ages: 70 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Zhejiang Cancer Hospital recruiting for?

Zhejiang Cancer Hospital is the lead sponsor of 11 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.